Crispr Therapeutics announces license agreement with KSQ Therapeutics for IP
Crispr Therapeutics announced a license agreement whereby Crispr Therapeutics will gain access to KSQ intellectual property, or IP, for editing certain novel gene targets in its allogeneic oncology cell therapy programs, and KSQ will gain access to Crispr Therapeutics' IP for editing novel gene targets identified by KSQ as part of its current and future engineered tumor infiltrating lymphocyte cell programs. The financial terms of the agreement are not being disclosed. The gene targets within the scope of the license agreement were identified using KSQ's proprietary Crispromics drug discovery engine, which allows genome-scale, in vivo validated, unbiased drug discovery. These specific targets were uncovered in screens to identify genetic edits that could enhance the functionality and quality of adoptive cell therapies in oncology.